A Look at Johnson & Johnson P/E Relative to Its Competitors
Johnson & Johnson has a lower P/E than the aggregate P/E of 25.34 of the Pharmaceuticals industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
